Literature DB >> 10541436

DNA priming-protein boosting enhances both antigen-specific antibody and Th1-type cellular immune responses in a murine herpes simplex virus-2 gD vaccine model.

J I Sin1, M Bagarazzi, C Pachuk, D B Weiner.   

Abstract

It has previously been reported that herpes simplex virus (HSV)-2 gD DNA vaccine preferentially induces T-helper (Th) 1-type cellular immune responses, whereas the literature supports the view that subunit vaccines tend to induce potent antibody responses, supporting a Th2 bias. Here, using an HSV gD vaccine model, we investigated whether priming and boosting with a DNA or protein vaccine could induce both potent antibody and Th1-type cellular immune responses. When animals were primed with DNA and boosted with protein, both antibody and Th-cell proliferative responses were significantly enhanced. Furthermore, production of Th1-type cytokines (interleukin-2, interferon-gamma) was enhanced by DNA priming-protein boosting. In contrast, protein priming-DNA boosting produced antibody levels similar to those following protein-protein vaccination but failed to further enhance Th-cell proliferative responses or cytokine production. DNA priming-protein boosting resulted in an increased IgG2a isotype (a Th1 indicator) profile, similar to that induced by DNA-DNA vaccination, whereas protein priming-DNA boosting caused an increased IgG1 isotype (a Th2 indicator) profile similar to that seen after protein-protein vaccination. This result indicates that preferential induction of IgG1 or IgG2a isotype is determined by the type of priming vaccine used. Thus, this study suggests that HSV DNA priming-protein boosting could elicit both potent Th1-type cellular immune responses and antibody responses, both of which likely are important for protection against HSV infection.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10541436     DOI: 10.1089/104454999314917

Source DB:  PubMed          Journal:  DNA Cell Biol        ISSN: 1044-5498            Impact factor:   3.311


  16 in total

Review 1.  Combination DNA plus protein HIV vaccines.

Authors:  Shan Lu
Journal:  Springer Semin Immunopathol       Date:  2006-09-21

2.  DNA vaccine molecular adjuvants SP-D-BAFF and SP-D-APRIL enhance anti-gp120 immune response and increase HIV-1 neutralizing antibody titers.

Authors:  Sachin Gupta; Emily S Clark; James M Termini; Justin Boucher; Saravana Kanagavelu; Celia C LeBranche; Sakhi Abraham; David C Montefiori; Wasif N Khan; Geoffrey W Stone
Journal:  J Virol       Date:  2015-01-28       Impact factor: 5.103

3.  HIV-specific humoral responses benefit from stronger prime in phase Ib clinical trial.

Authors:  Pierre-Alexandre Bart; Yunda Huang; Shelly T Karuna; Samuel Chappuis; Julien Gaillard; Nidhi Kochar; Xiaoying Shen; Mary A Allen; Song Ding; John Hural; Hua-Xin Liao; Barton F Haynes; Barney S Graham; Peter B Gilbert; M Juliana McElrath; David C Montefiori; Georgia D Tomaras; Giuseppe Pantaleo; Nicole Frahm
Journal:  J Clin Invest       Date:  2014-10-01       Impact factor: 14.808

4.  Improved immunogenicity and protective efficacy of a tuberculosis DNA vaccine encoding Ag85 by protein boosting.

Authors:  A Tanghe; S D'Souza; V Rosseels; O Denis; T H Ottenhoff; W Dalemans; C Wheeler; K Huygen
Journal:  Infect Immun       Date:  2001-05       Impact factor: 3.441

Review 5.  Vaccines against genital herpes: progress and limitations.

Authors:  Lynda A Morrison
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 6.  DNA vaccines against human immunodeficiency virus type 1 in the past decade.

Authors:  Malavika Giri; Kenneth E Ugen; David B Weiner
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

Review 7.  Heterologous prime-boost vaccination.

Authors:  Shan Lu
Journal:  Curr Opin Immunol       Date:  2009-06-06       Impact factor: 7.486

8.  Inactivated HSV-2 in MPL/alum adjuvant provides nearly complete protection against genital infection and shedding following long term challenge and rechallenge.

Authors:  Christopher S Morello; Kimberly A Kraynyak; Michael S Levinson; Zhijiang Chen; Kuo-Fen Lee; Deborah H Spector
Journal:  Vaccine       Date:  2012-09-01       Impact factor: 3.641

9.  Heterologous vaccination targeting prostatic acid phosphatase (PAP) using DNA and Listeria vaccines elicits superior anti-tumor immunity dependent on CD4+ T cells elicited by DNA priming.

Authors:  Laura E Johnson; Dirk Brockstedt; Meredith Leong; Peter Lauer; Erin Theisen; John-Demian Sauer; Douglas G McNeel
Journal:  Oncoimmunology       Date:  2018-05-07       Impact factor: 8.110

10.  Lysine: Is it worth more?

Authors:  D Datta; A Bhinge; V Chandran
Journal:  Cytotechnology       Date:  2001-07       Impact factor: 2.058

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.